Abstract | Objective: Approach: Results: Serum PCSK9 increased during the acute phase and this response was modestly associated with neutrophil counts (r=0.24, p=0.009) and presence of hypercholesterolaemia (r=0.019, p=0.045), but was not modified by tocilizumab. However, a modifying effect of tocilizumab on PCSK9 levels was observed in patients with hypercholesterolaemia (p=0.024, repeated measures analysis of variance) and this effect was strongly correlated with the decrease in neutrophils (r=0.66, p=0.004). Conclusions: Our study suggests that patients with a more atherogenic profile may benefit from anti-IL-6 therapy with regard to PCSK9. Trial registration number: NCT01491074.
|
Authors | Thor Ueland, Ola Kleveland, Annika E Michelsen, Rune Wiseth, Jan Kristian Damås, Pål Aukrust, Lars Gullestad, Bente Halvorsen, Arne Yndestad |
Journal | Open heart
(Open Heart)
2018
Vol. 5
Issue 2
Pg. e000765
ISSN: 2053-3624 [Print] England |
PMID | 30258647
(Publication Type: Journal Article)
|